ARS Pharmaceuticals (NASDAQ: SPRY) revenue
ARS Pharmaceuticals reported revenue of $84.3m for fiscal 2025, 5.5% less than in fiscal 2024 ($89.1m). Since fiscal 2021 its revenue has grown by 1,430.7%, an average growth of 97.8% a year.
ARS Pharmaceuticals's best year of the last 5 was fiscal 2024. The biggest drop was in fiscal 2023, −97.7%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $84.3m | −5.5% | −$179.4m | −212.9% |
| 2024 | $89.1m | +297,063.3% | −$3.1m | −3.5% |
| 2023 | $0.0m | −97.7% | −$67.5m | −225,066.7% |
| 2022 | $1.3m | −76.1% | −$35.5m | −2,698.8% |
| 2021 | $5.5m | — | −$19.5m | −353.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
ARS Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, ARS Pharmaceuticals ranks 296th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; ARS Pharmaceuticals, −5.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 294th | Delcath Systems | $85.2m | 129.1% |
| 295th | 4D Molecular Therapeutics | $85.2m | 230,194.6% |
| 296th | ARS Pharmaceuticals | $84.3m | −5.5% |
| 297th | Nurix Therapeutics | $84.0m | 54.0% |
| 298th | Iradimed | $83.8m | 14.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of ARS Pharmaceuticals
- How much revenue did ARS Pharmaceuticals make in fiscal 2025?
- ARS Pharmaceuticals reported revenue of $84.3m for fiscal 2025, compared with $89.1m in fiscal 2024.
- How much has the revenue of ARS Pharmaceuticals grown?
- Between fiscal 2021 and fiscal 2025 it went from $5.5m to $84.3m: 1,430.7% more, an average growth of 97.8% a year.
- What was the best year for revenue at ARS Pharmaceuticals?
- Of its last 5 fiscal years, fiscal 2024, with $89.1m.
- Where does ARS Pharmaceuticals rank in its sector by revenue?
- It ranks 296th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for ARS Pharmaceuticals come from?
- From the annual report (Form 10-K) that ARS Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that ARS Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on ARS Pharmaceuticals: the ARS Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.